Posted by Michael Wonder on 10 May 2022
HIRA unveils detailed reimbursement criteria for Olumiant, Rinvoq
10 May 2022 - Lilly’s Olumiant (baricitinib) and Abbvie’s Rinvoq (upadacitinib) got health insurance benefits starting from May 1 to treat severe atopic dermatitis.
Patients who used the two drugs to treat severe atopic dermatitis without health insurance will be able to get insurance benefits as long as they meet certain criteria, the government said.
